CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that its Board of Directors is continuing its previously announced process to review strategic alternatives to maximize shareholder value. The strategic alternatives the Board of Directors is reviewing include, but are not limited to, a sale, merger or other business combination of CPEX with a third party or a monetization of CPEX's assets including its rights to receive royalties and milestone payments.
“Since we announced our intentions to explore strategic alternatives in May, we have initiated and participated in discussions with interested parties”
"Since we announced our intentions to explore strategic alternatives in May, we have initiated and participated in discussions with interested parties," stated John Sedor, President and CEO. "We remain actively engaged in discussions regarding potential strategic transactions and will make a public announcement when and if a definitive agreement is reached or our Board decides to terminate the process. While there can be no assurance that this process will result in any transaction, we remain committed to enhancing and delivering value to our shareholders."
ADHD medications show minimal impact on heart health in large study